Progenics Pharmaceuticals (PGNX) Short Interest Ratio & Short Volume

Short interest is the volume of Progenics Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 5,760,000 shares of PGNX short. 7.35% of Progenics Pharmaceuticals' shares are currently sold short. Learn More on Progenics Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PGNX shares currently have a short interest ratio of 7.0. Learn More on Progenics Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.35% of Progenics Pharmaceuticals' floating shares are currently sold short.

Progenics Pharmaceuticals saw a drop in short interest in June. As of June 15th, there was short interest totaling 5,760,000 shares, a drop of 1.2% from the previous total of 5,830,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Progenics Pharmaceuticals currently has issued a total of 86,597,000 shares. Some of Progenics Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Progenics Pharmaceuticals currently has a public float of 78,350,000 shares.

7.35% of Progenics Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Progenics Pharmaceuticals: XOMA Co. (2.42%), Lexicon Pharmaceuticals, Inc. (8.17%), Vanda Pharmaceuticals Inc. (3.80%), Verastem, Inc. (3.94%), Merrimack Pharmaceuticals, Inc. (5.62%), Rigel Pharmaceuticals, Inc. (2.95%), Regulus Therapeutics Inc. (10.92%), Syros Pharmaceuticals, Inc. (10.10%), Selecta Biosciences, Inc. (7.18%), Emergent BioSolutions Inc. (11.76%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.67 billion), Match Group, Inc. ($3.64 billion), Wayfair Inc. ($3.47 billion), Tesla, Inc. ($3.00 billion), Ecolab Inc. ($2.97 billion), Morgan Stanley ($2.93 billion), The Charles Schwab Co. ($2.70 billion), Carnival Co. & plc ($2.38 billion), The Clorox Company ($2.29 billion), and Aon plc ($2.24 billion). View all of the most shorted stocks.

Short selling PGNX is an investing strategy that aims to generate trading profit from Progenics Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Progenics Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PGNX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PGNX, twice per month. The most recent reporting period available is June, 15 2020.